Replies to post #461973 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

It's a feel-good factor for management; they need some work to appear busy by following OLE sites

What a revelation--thanks much. I need to immediately contact SAVA's management and that of numerous other biotech companies and ask them why they are wasting a lot of shareholder money with open label extension programs. Shame on SAVA for caving to over 700 patients requests (90% of those who have completed a Phase III study) and currently offering Simufilam at over 100 clinical sites.